Stockscreener 앱 받기
32.84
0.61%
-0.20
시간 외 거래:
32.19
-0.65
-1.98%
전일 마감가:
$33.04
열려 있는:
$33
하루 거래량:
668.87K
Relative Volume:
0.46
시가총액:
$2.60B
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-12.03
EPS:
-2.73
순현금흐름:
$-97.30M
1주 성능:
+2.85%
1개월 성능:
-11.58%
6개월 성능:
+129.33%
1년 성능:
+228.40%
1일 변동 폭
$32.25
$33.63
1주일 범위
$30.96
$34.65
52주 변동 폭
$8.241
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
32.84 | 2.61B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Uncovering a 53.98% Potential Upside in Biotech - directorstalkinterviews.com
What is HC Wainwright's Forecast for MLYS FY2030 Earnings? - MarketBeat
Insider Trends: How sensitive is Mineralys Therapeutics Inc to inflationWeekly Trade Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Aug EndMonth: Will CMPS benefit from rate cutsJuly 2025 Pullbacks & AI Powered Market Entry Ideas - baoquankhu1.vn
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Avoiding Lag: Real-Time Signals in (MLYS) Movement - Stock Traders Daily
Mineralys Therapeutics Inc call volume above normal and directionally bullish - TipRanks
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook - MSN
Relative Strength Alert For Mineralys Therapeutics - Nasdaq
Rodman sells Mineralys (MLYS) shares for $13,353 - Investing.com
Rodman sells Mineralys (MLYS) shares for $13,353 By Investing.com - Investing.com Nigeria
David Malcom Rodman Sells 416 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Awards New Hire Stock Option as Hypertension Pipeline Advances - MSN
Fed Watch: What is Mineralys Therapeutics Incs revenue forecast2025 Market Overview & Smart Swing Trading Alerts - baoquankhu1.vn
Activity Recap: Is EKSO a potential multi baggerAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Are Mineralys Therapeutics’ (MLYS) Executive Stock Plans Aligned With Lorundrostat’s Emerging Investment Story? - Sahm
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 7,709 Shares of Stock - MarketBeat
David Malcom Rodman Sells 11,367 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Sell Signal: Is Mineralys Therapeutics Inc. part of any major index2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Mineralys Therapeutics MLYS officer sells $277k in stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $529,618.32 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock By Investing.com - Investing.com Canada
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $72,195.90 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $205,167.36 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) CFO Sells $345,762.12 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock - Investing.com
Mineralys Therapeutics MLYS officer sells $277k in stock - Investing.com
Buybacks Report: Will Mineralys Therapeutics Inc outperform tech stocksQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Patterns Watch: Whats Mineralys Therapeutics Incs historical returnJuly 2025 Rallies & Safe Capital Investment Plans - baoquankhu1.vn
Mineralys Targets Sleep Apnea and Hypertension With Lorundrostat: What Investors Should Watch - TipRanks
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Unveiling a 54% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Discipline and Rules-Based Execution in MLYS Response - Stock Traders Daily
Trend Recap: Whats the RSI of Mineralys Therapeutics Inc stockJuly 2025 PostEarnings & Reliable Breakout Forecasts - baoquankhu1.vn
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - ADVFN
Will Mineralys Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Outlook & Risk Adjusted Buy/Sell Alerts - Улправда
Mineralys Therapeutics (MLYS) Stock Analysis Report | Financials & Insights - Benzinga España
Can Mineralys Therapeutics Inc. stock attract ESG capital inflowsEarnings Risk Summary & Weekly Breakout Watchlists - ulpravda.ru
Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 7%Here's What Happened - MarketBeat
Is Mineralys Therapeutics Inc. stock a contrarian buyJuly 2025 Breakouts & Verified Momentum Watchlists - Улправда
Why Mineralys Therapeutics Inc. stock could outperform in 2025Quarterly Growth Report & Free Fast Entry Momentum Trade Alerts - Улправда
Mineralys Flags Key Data Readouts as Lorundrostat Nears FDA Decision - mychesco.com
Mineralys Therapeutics, Inc.Common Stock (NQ: MLYS - FinancialContent
Mineralys Therapeutics Insider Sold Shares Worth $9,261,028, According to a Recent SEC Filing - marketscreener.com
MLYSMineralys Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 70,037 Shares of Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $6,748,879.30 in Stock - MarketBeat
Mineralys Therapeutics CMO Sells Over $9 Million in Company Stock - TradingView — Track All Markets
Mineralys Therapeutics(MLYS.US) Officer Sells US$9.26 Million in Common Stock - 富途牛牛
Mineralys Therapeutics: Lorundrostat’s Broad Efficacy, Favorable Safety, and Upside Indications Support Buy Rating on MLYS - TipRanks
Mineralys Therapeutics filed NDA for lorundrostat to U.S. FDA in late 2025 - marketscreener.com
Mineralys updates lorundrostat program and upcoming data milestones - TipRanks
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):